MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

long-term compliance issues, pricing pressure, and new competition. Lilly’s third-quarter revenue grew 20% as the sale of rights to the Zyprexa franchise (more than $1.4 billion in sales in the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst ...

(Reuters) -Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long ...

WASHINGTON (Reuters) - Vice President Kamala Harris on the campaign trail has frequently touted capping the price of insulin at $35 a month as a major accomplishment of the Biden administration ...

Tirzepatide demonstrates greater efficacy than long-acting and ultra-long-acting insulin for managing type 2 diabetes, yielding greater improvements in glycemic control, weight loss, and ...

Eli Lilly’s (NYSE:LLY) released study results on Monday that showed the long-term efficacy of mirikizumab, marketed under the brand name Omvoh, against both ulcerative colitis (UC) and Crohn's ...

On Monday, Eli Lilly And Co (NYSE:LLY ... The studies showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis and Crohn’s disease.

Additionally, Lilly has a combination study in ulcerative colitis with mirikizumab and eltrekibart. The studies showed patients treated with mirikizumab sustained stable, long-term remission in ...